A Phase 2, Double-Blind, Randomized, Placebo- Controlled, Multicenter Study to Evaluate the Clinical Effect, Pharmacodynamic, Pharmacokinetic and Safety Profile of PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations
A Phase 2, Double-Blind, Randomized, Placebo- Controlled, Multicenter Study to Evaluate the Clinical Effect, Pharmacodynamic, Pharmacokinetic and Safety Profile of PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations secchiarolim Wed, 06/03/2026 - 21:23 PF-06823859 PHASE II Fri, 07/07/2023 - 12:00 Tue, 11/18/2025 - 12:00 NCT
